ReviewInformatics in medicine unlocked2021
The journey of antimalarial drugs against SARS-CoV-2: Review article.
Review in Informatics in medicine unlocked, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- A Systematic Review of the Global Intervention for SARS-CoV-2 Combating: From Drugs Repurposing to Molnupiravir Approval.Drug design, development and therapy · 2022Pooled it
- Investigating the anti-inflammatory potential ofRSC advances · 2024Article
- Recent advances in COVID-19-induced liver injury: causes, diagnosis, and management.Inflammopharmacology · 2024Review
- Squaramide Tethered Clindamycin, Chloroquine, and Mortiamide Hybrids: Design, Synthesis, and Antimalarial Activity.ACS medicinal chemistry letters · 2023Article
- Ligand-based design, synthesis, computational insights, andJournal of enzyme inhibition and medicinal chemistry · 2022Article
- Article
- Anticoagulants as Potential SARS-CoV-2 MInternational journal of molecular sciences · 2022Article
- Robust antiviral activity of commonly prescribed antidepressants against emerging coronaviruses: in vitro and in silico drug repurposing studies.Scientific reports · 2022Article
- Fluorine in Medicinal Chemistry: In Perspective to COVID-19.ACS omega · 2022Review
- Review
- Coronavirus Disease (COVID-19) Control between Drug Repurposing and Vaccination: A Comprehensive Overview.Vaccines · 2021Review
- Naturally Available Flavonoid Aglycones as Potential Antiviral Drug Candidates against SARS-CoV-2.Molecules (Basel, Switzerland) · 2021Article
- β-Blockers bearing hydroxyethylamine and hydroxyethylene as potential SARS-CoV-2 Mpro inhibitors: rational based design,RSC advances · 2021Article
- Article
- A Drug Repurposing Approach for Antimalarials Interfering with SARS-CoV-2 Spike Protein Receptor Binding Domain (RBD) and Human Angiotensin-Converting Enzyme 2 (ACE2).Pharmaceuticals (Basel, Switzerland) · 2021Article
- Investigating the structure-activity relationship of marine natural polyketides as promising SARS-CoV-2 main protease inhibitors.RSC advances · 2021Article
- Article
- Just a Reflection: Does Drug Repurposing Perpetuate Sex-Gender Bias in the Safety Profile?Pharmaceuticals (Basel, Switzerland) · 2021Review
- Computational Insights on the Potential of Some NSAIDs for Treating COVID-19: Priority Set and Lead Optimization.Molecules (Basel, Switzerland) · 2021Article
- Bioactive Polyphenolic Compounds Showing Strong Antiviral Activities against Severe Acute Respiratory Syndrome Coronavirus 2.Pathogens (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The recent outbreak of coronavirus pandemic (COVID-19) introduced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has greatly affected the global public health. This pandemic disease became particularly threatening after the start of a new wave. Vaccines of tested efficacy to stop COVID-19 infection are being investigated vigorously worldwide. Currently, some specific drugs have been authorized for COVID-19, but the improvement of antivirals requires time. Hence, a faster way of treatment is done by drug repurposing. Repurposing of drugs is promising for treating and reducing the symptoms of the disease, and it a fast, easy, and safe method to address the crisis, because of their previously known applications. Some antimalarial drugs, especially chloroquine and hydroxychloroquine, have been repurposed, as they exhibited promising results
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.